JohnsonVA, CalvezV, GünthardHFet al.2011 Update of the drug resistance mutations in HIV-1. Top Antivir Med, 2011; 19:156–164.
2.
HavlirDV, BassetR, LevitanDet al.Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA, 2001; 286:171–179.
3.
SklarPA, WardDJ, BakerRKet al. the HIV Outpatients Study (HOPS) Investigators. Prevalence and clinical correlates of HIV viremia (‘blips') in patients with previous suppression below the limits of quantification. AIDS, 2002; 16:2035–2041.
4.
MooreAL, YouleM, LipmanMet al.Raised viral load in patients with viral suppression highly active antiretroviral therapy: Transient increase or treatment failure?AIDS, 2002; 16:615–618.
5.
GreubG, Cozzi-LepriA, LedergerberBet al. for the Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS, 2002; 16:1967–1969.
6.
MasquelierB, PereiraE, PeytavinGet al.Intermittent viremia during first-line, protease inhibitors containing therapy: Significance and relationship with drug resistance. J Clin Virol, 2005; 33:75–78.
7.
MaciasJ, PalomaresJC, MiraJAet al.Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect, 2005; 51:195–200.
8.
SungkanuparphS, OvertonET, SeyfriedW, GrogerRK, FraserVJ, PowderlyWG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis, 2005; 41:1326–1332.
9.
WillbergCB, McConnellJJ, ErikssonEMet al.Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog, 2008; 4:1–13.
10.
KalichmanSC, RompaD. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect, 2003; 79:59–61.
11.
KalichmanSC, CherryC, AmaralCMet al.Adherence to antiretroviral therapy and HIV transmission risks: Implications for test-and-treat approaches to HIV prevention. AIDS Patient Care STDs, 2010; 24:271–277.
12.
SabinoEC, DiazRS, BrigidoLFet al.Distribution of HIV-1 subtypes seen in an AIDS clinic in São Paulo City, Brazil. AIDS, 1996; 10:1579–1584.
